High body mass index correlates with increased risk of venous irritation by vinorelbine infusion

Japanese Journal of Clinical Oncology

Volumn 34, Issue 4, 2004, Pages 206-209

  Yoh, Kiyotaka ^a   Niho, Seiji ^a   Goto, Koichi ^a   Ohmatsu, Hironobu ^a   Kubota, Kaoru ^a   Kakinuma, Ryutaro ^a   Nishiwaki, Yutaka ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Body mass index; Lung cancer; Phlebitis; Venous irritation; Vinorelbine

Indexed keywords

CISPLATIN; GEMCITABINE; MITOMYCIN C; NAVELBINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MITOMYCIN; VINBLASTINE;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG RESPONSE; ERYTHEMA; FEMALE; HUMAN; INCIDENCE; INJECTION PAIN; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHLEBITIS; PRURITUS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SKIN MANIFESTATION; SKIN NECROSIS; SKIN ULCER; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VEIN DISEASE; CHEMICALLY INDUCED DISORDER; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCINS; PHLEBITIS; RETROSPECTIVE STUDIES; RISK FACTORS; VINBLASTINE;

EID: 2942635701     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh029     Document Type: Article

References (19)

1. Potier P. The synthesis of Navelbine, prototype of a new series of vinblastine derivatives. Semin Oncol 1989;16(2 Suppl 4):2-4.
2. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Ann J Clin Oncol 1991;14:115-9.
3. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-52.
4. Devizzi L, Santoro A, Bonfante V, Viviani S, Bonadonna G. Vinorelbine: A new promising drug in Hodgkin's disease. Leuk Lymphoma 1996;22: 409-14.
5. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
6. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, van Glabbeke M, Noseda MA, Ardizzoni A, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993;29A:1720-2.
7. Rittenberg CN, Gralla RJ, Rehmeyer TA. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine). Oncol Nurs Forum 1995;22:707-10.
8. Lacava JA, Leone BA, Machiavelli M, Romero AO, Perez JE, Elem YL, et al. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 1997;15:604-9.
9. Leone BA, Vallejo CT, Romero AO, Perez JE, Cuevas MA, Lacava JA, et al. Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2993-9.
10. Iaffaioli RV, Tortoriello A, Facchini G, Santangelo M, De Sena G, Gesue G, et al. A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer. Br J Cancer 1995;72:1256-8.
11. Vassilomanolakis M, Koumakis G, Barbounis V, Orphanos G, Efremidis A. Prevention of vinorelbine phlebitis with cimetidine. A two-step design study. Support Care Cancer 2001;9:108-11.
12. Maisano R, Adamo V, Toscano G, Chiofalo G, Pergolizzi S, Scimone A. Defibrotide in the prevention of venous irritation by vinorelbine administration. Anticancer Res 1997;17:2775-7.
13. Lozano M, Muro H, Triguboff E, Schmilovich A, Reale M, Gil DE. A randomized trial for effective prevention of navelbine (NVB) related phlebitis. Proc Am Soc Clin Oncol 1995;14:1766.
14. Shirai K. Evaluation of obesity and diagnostic criteria of obesity as a disease for Japanese. Nippon Rinsho 2001;59:578-85 (in Japanese).
15. Winkler UH. Obesity and thrombotic vascular diseases. Zentralbl Gynakol 1998;120:246-50.
16. Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994;21 (5 Suppl 10):42-6.
17. Botana LM, Arnaez E, Vieytes MR, Alfonso A, Bujan MJ, Louzao MC, et al. Non-immunological release of histamine from rat mast cells elicited by antineoplastic agents. Cancer Chemother Pharmacol 1992;29:495-8.
18. Estevez MD, Vieytes MR, Louzao MC, Alfonso A, Vilarino N, Botana LM. The antineoplastic drug vinorelbine activates non-immunological histamine release from rat mast cells. Inflamm Res 1997;46:119-24.
19. Nakayama S, Matsubara N, Sakai T, Aso N. The incidence of phlebitis in the patients administrated vinorelbine by intravenous bolus injection - a retrospective study. Gan To Kagaku Ryoho 2002;29:633-5 (in Japanese).